<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30327858</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>17</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1432-1963</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>16</Day>                    </PubDate>                </JournalIssue>                <Title>Der Pathologe</Title>                <ISOAbbreviation>Pathologe</ISOAbbreviation>            </Journal>            <ArticleTitle>[Standardized determination of tumor-infiltrating lymphocytes in breast cancer : A prognostic marker for histological diagnosis].</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00292-018-0530-y</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Tumor-infiltrating lymphocytes (TILs) have been identified as prognostic parameter in breast cancer.</AbstractText>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this review article is to provide an overview on the clinical and analytical validation of TILs in breast cancer.</AbstractText>                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Summary of international guidelines of the TIL working group as well as clinical and translational studies.</AbstractText>                <AbstractText Label="RESULTS, CONCLUSIONS" NlmCategory="UNASSIGNED">Breast carcinomas with a high TIL level have an improved response to neoadjuvant chemotherapy. Triple-negative and HER2-positive carcinomas with increased TIL levels have improved survival. TILs are a new prognostic biomarker for routine histopathological diagnosis.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Denkert</LastName>                    <ForeName>C</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Institut für Pathologie der Charité, Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland. carsten.denkert@charite.de.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Deutsches Konsortium für Translationale Krebsforschung (DKTK), Standort Berlin, Berlin, Deutschland. carsten.denkert@charite.de.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Loibl</LastName>                    <ForeName>S</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>German Breast Group, Neu-Isenburg, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Budczies</LastName>                    <ForeName>J</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Institut für Pathologie der Charité, Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Institut für Pathologie, Universität Heidelberg, Heidelberg, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wienert</LastName>                    <ForeName>S</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Institut für Pathologie der Charité, Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>VMscope GmbH, Berlin, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Klauschen</LastName>                    <ForeName>F</ForeName>                    <Initials>F</Initials>                    <AffiliationInfo>                        <Affiliation>Institut für Pathologie der Charité, Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>ger</Language>            <PublicationTypeList>                <PublicationType UI="D004740">English Abstract</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>            <VernacularTitle>Standardisierte Bestimmung tumorinfiltrierender Lymphozyten beim Mammakarzinom : Ein prognostischer Marker für die histologische Diagnostik.</VernacularTitle>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Germany</Country>            <MedlineTA>Pathologe</MedlineTA>            <NlmUniqueID>8006541</NlmUniqueID>            <ISSNLinking>0172-8113</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Biomarkers</Keyword>            <Keyword MajorTopicYN="N">Breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">Immune infiltrate</Keyword>            <Keyword MajorTopicYN="N">Neoadjuvant therapy</Keyword>            <Keyword MajorTopicYN="N">Prognosis</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30327858</ArticleId>            <ArticleId IdType="doi">10.1007/s00292-018-0530-y</ArticleId>            <ArticleId IdType="pii">10.1007/s00292-018-0530-y</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>